Vigil Neuroscience Inc (VIGL) Actualités

Form 8-K - Current report

Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease

- Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927...

Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones

– On track to report data from Phase 1 clinical trial evaluating VG-3927 for the treatment of Alzheimer’s...

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Vigil Neuroscience to Present at Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update

- Final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP planned for first half of...

Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference

WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage...

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927

WATERTOWN, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a...

Vigil Neuroscience to Present at Cantor Global Healthcare Conference

WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a...